Literature DB >> 29508099

Characteristic deterioration of ADAS-Jcog subscale scores and correlations with regional cerebral blood flow reductions in Alzheimer's disease.

Fumihito Yoshii1,2, Chikako Kawaguchi3, Saori Kohara4, Mie Shimizu4, Hiroe Onaka4, Masafuchi Ryo5, Wakoh Takahashi5.   

Abstract

The Alzheimer Disease Assessment Scale (Japanese version) cognitive subscale (ADAS-Jcog) is composed of a number of subscale tasks. However, it is not clear which subscale tasks are most susceptible to impairment in Alzheimer's disease (AD) or what is the relationship between reduction in regional cerebral blood flow (rCBF) and decreased ADAS-Jcog scores. Subjects were 32 AD patients, aged 52-86 years. We examined the relationship between subscale tasks that showed marked score changes and brain regions that showed reduced rCBF over a 2-year period. rCBF was measured by single-photon emission computed tomography (SPECT) with technetium-99m ethyl cysteinate dimer (99mTc-ECD), and the SPECT imaging data were analyzed with the easy Z-score imaging system (eZIS) and voxel-based stereotactic extraction estimation (vbSEE) methods. Total score of ADAS-Jcog deteriorated from 19.5 ± 7.0 to 35.7 ± 15.2 after 2 years. Subscale scores were significantly worse in all fields, particularly in orientation, word recall, remembering test instructions, commands, constructional praxis, and ideational praxis, in that order. Significant correlations were found between (1) word recall and commands and rCBF in the left middle temporal lobe, (2) naming objects/fingers and rCBF in the left temporal (middle, inferior) lobe, and (3) constructional and ideational praxis and rCBF in the right parietal (superior, inferior) lobe, temporal (superior, middle) lobe, angular gyrus, and cingulate gyrus. We identified the brain regions associated with specifically impaired subscales of ADAS-Jcog during progressive deterioration of AD over 2 years.

Entities:  

Keywords:  Alzheimer Disease Assessment Scale cognitive subscale (ADAS-cog); Alzheimer’s disease; Cerebral blood flow; Single-photon emission computed tomography (SPECT)

Mesh:

Substances:

Year:  2018        PMID: 29508099     DOI: 10.1007/s10072-018-3277-6

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  2 in total

1.  A New Serum Biomarker Set to Detect Mild Cognitive Impairment and Alzheimer's Disease by Peptidome Technology.

Authors:  Koji Abe; Jingwei Shang; Xiaowen Shi; Toru Yamashita; Nozomi Hishikawa; Mami Takemoto; Ryuta Morihara; Yumiko Nakano; Yasuyuki Ohta; Kentaro Deguchi; Masaki Ikeda; Yoshio Ikeda; Koichi Okamoto; Mikio Shoji; Masamitsu Takatama; Motohisa Kojo; Takeshi Kuroda; Kenjiro Ono; Noriyuki Kimura; Etsuro Matsubara; Yosuke Osakada; Yosuke Wakutani; Yoshiki Takao; Yasuto Higashi; Kyoichi Asada; Takehito Senga; Lyang-Ja Lee; Kenji Tanaka
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

2.  Psychometric properties of Cognitive Instruments in Vascular Dementia and Alzheimer's disease: a neuropsychological study.

Authors:  Juliana Francisca Cecato; Everton Balduino; Débora Fuentes; José Eduardo Martinelli
Journal:  Clinics (Sao Paulo)       Date:  2020-03-09       Impact factor: 2.365

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.